Tags : Everest

Pharma

Everest Enter into an Exclusive License Agreement with Sinovent and

Shots: Sinovent & SinoMab to receive $12M up front, ~$549M in development, regulatory & commercial milestone along with royalties on net sales of a product The agreement will strengthen Everest’s leadership in developing novel therapies for renal disease in Greater China & Asia. The agreement also includes technology transfer of manufacturing process to Everest for […]Read More

Biotech COVID-19

Everest Signs a License Agreement with Providence to Advance mRNA

Shots: Providence to receive $100M up front for Providence’s PTX-COVID19-B, mRNA technology & other products, ~$300M upon achievement of milestones, $100M in profit-sharing along with royalties in Greater China & Singapore. Providence is also eligible to receive royalties based on vaccine sales in Everest Territories Everest gains rights to Providence’s PTX-COVID19-B in Greater China, Asia, […]Read More